Surg Cosmet Dermatol. 2026;18(2):1-4
Amivantamab is a bispecific anti-EGFR and anti-MET monoclonal antibody indicated for non-small cell lung cancer harboring EGFR exon 20 insertion mutations. Although effective, it may cause cutaneous adverse events such as paronychia and pyogenic granulomas. We report a case of periungual pyogenic granuloma in a patient undergoing amivantamab therapy, emphasizing the causal relationship, clinical evolution, and surgical management. Early recognition and a multidisciplinary approach are crucial to maintain oncological treatment while ensuring adequate control of dermatologic manifestations.
Keywords: Granuloma, Pyogenic. Drug-Related Side Effects and Adverse Reactions; Molecular Targeted Therapy
All content the journal, except where identified, under the Creative Commons Attribution 4.0 International licence - ISSN-e 1984-8773
